Sökning: onr:"swepub:oai:lup.lub.lu.se:717b7c46-5247-473a-b141-582f8bbe4c68" >
Epidemiology and Et...
Epidemiology and Etiology of AML
-
- Juliusson, Gunnar (författare)
- Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital
-
- Lazarevic, Vladimir (författare)
- Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital
-
- Lehmann, Sören (författare)
- Uppsala University,Karolinska Institute
-
visa fler...
-
Röllig, Christoph (redaktör/utgivare)
-
Ossenkoppele, Gert J. (redaktör/utgivare)
-
visa färre...
-
(creator_code:org_t)
- 2021-05-19
- 2021
- Engelska 22 s.
-
Ingår i: Acute Myeloid Leukemia. - Cham : Springer International Publishing. - 2197-9766 .- 2197-9774. - 9783030726782 - 9783030726768 ; , s. 1-22
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Acute myeloid leukemia (AML) is a grave disease with an incidence of 4 per 100,000 a year. It can present in all ages, but the median age is 70 years. One-third of such patients have secondary AML, that is, AML following chemoradiotherapy or a transformation from previous myelodysplastic syndrome (MDS) or myeloproliferative neoplasia. A combination of genetic, epigenetic, and environmental factors may be responsible for the development of most cases of AML. The pathogenesis of AML is characterized by the serial acquisition of somatic mutations and several genes are recurrently mutated in AML. Exposures to benzene, cigarette smoking, pesticides, embalming fluids, accidental or professional ionization radiation, therapeutic radiotherapy, and radioactive I-131 therapy can cause AML with or without a preceding MDS phase. Alkylating agents (e.g., melphalan, cyclophosphamide), topoisomerase-II inhibitors (e.g., etoposide, doxorubicin), and other drugs (e.g., azathioprine) are described to be associated with the development of therapy-related AML (t-AML). Furthermore, about 5–15% of adults and 4–13% of pediatric patients with MDS or AML carry germline pathogenic variants in cancer susceptibility genes. Individuals with clonal hematopoiesis (CHIP) progress to AML at a rate of about 1% per year. Higher age of onset, obesity, previous autoimmune disease, and antecedent MDS or MPN are associated with a risk for developing AML.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Benzene
- Diagnosis
- Exposure
- Hereditary conditions
- Incidence
- Mutations
- Prevalence
- Secondary AML
- Sex
- Survival
- t-AML
Publikations- och innehållstyp
- kap (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas